Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000216352 | SCV000274154 | pathogenic | Hereditary cancer-predisposing syndrome | 2015-02-20 | criteria provided, single submitter | clinical testing | The c.310_311dupCA pathogenic mutation, located in coding exon 3 of the SDHA gene, results from a duplication of CA at nucleotide position 310, causing a translational frameshift with a predicted alternate stop codon. Since frameshifts are typically deleterious in nature, this alteration is interpreted as a disease-causing mutation (ACMG Recommendations for Standards for Interpretation and Reporting of Sequence Variations. Revision 2007. Genet Med. 2008;10:294). |
Labcorp Genetics |
RCV002518274 | SCV003444264 | pathogenic | Mitochondrial complex II deficiency, nuclear type 1; Paragangliomas 5 | 2023-10-20 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Gln104Hisfs*25) in the SDHA gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SDHA are known to be pathogenic (PMID: 22974104, 24781757). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with SDHA-related conditions. For these reasons, this variant has been classified as Pathogenic. |
Baylor Genetics | RCV004567524 | SCV005056603 | likely pathogenic | Dilated cardiomyopathy 1GG | 2023-11-04 | criteria provided, single submitter | clinical testing |